The aim of this study was to verify the association of the ACTN3-R577X polymorphism with sarcopenia stage, according to the Revised European Consensus on the Definition and Diagnosis of Sarcopenia, in middle-aged and older adults, pre- and post- ST. In the 12-week longitudinal study, 71 middle-aged and older adults were evaluated; the participants were assigned to either control or intervention group. The intervention group underwent progressive ST three times a week. All participants underwent blood collection, DNA extraction, genotyping of the ACTN3-R577X polymorphism, anthropometric evaluations, and diagnostic tests for sarcopenia. The last two tests were repeated after 12 weeks. No association of the ACTN3-R577X polymorphism with sarcopenia stage was observed before and after 12 weeks. However, the intervention group remained non-sarcopenic (n = 25, p <0.05) or achieved changes in sarcopenia stage (from sarcopenic to non-sarcopenic) (n = 13, p <0.05). Our study demonstrates that progressive ST performed regularly can reverse or prevent sarcopenia regardless of genotype for the ACTN3-R577X polymorphism.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.archger.2023.105182 | DOI Listing |
Endocrine
December 2024
Εndocrinology Unit, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Background: Neuroendocrine neoplasms (NEN) are rare tumors arising from neuroendocrine cells most commonly in the gastrointestinal-tract. In recent years, advancements in therapeutics have increased survival rates in patients with NEN leading to a greater clinical burden compared to the general population.
Methods: The aim of this single-center case-control study was to investigate the incidence of low bone mass and changes in body composition in adult patients diagnosed with gastroenteropancreatic neuroendocrine tumors (GEPNET).
Rev Esp Med Nucl Imagen Mol (Engl Ed)
December 2024
Department of Radiology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey.
Aim: This study aimed to investigate the relationship between PET and CT parameters and sarcopenia, adipose tissue, and tumor metabolism in esophageal carcinoma(EC) and its impact on survival in EC.
Method: Our study included 122 EC patients who underwent PET/CT for staging. Muscle and adipose tissue characteristics were evaluated, including lumbar(L3) and cervical(C3) muscle areas, psoas major(PM) and sternocleidomastoid muscle(SCM) parameters, and PET parameters for visceral and subcutaneous adipose tissue(SAT).
J Vasc Surg
December 2024
Department of Vascular Surgery, st. Antonius Hospital Nieuwegein, the Netherlands.
Introduction: The 2019 Global Vascular Guidelines recommend risk assessment for evidence based revascularization based on the acronym PLAN; Patient risk, Limb severity and ANatomical complexity of disease. This meta-analysis compares a multitude of prognostic tests within these categories.
Methods: A systematic review and meta-analysis of tests that estimated 1 year major event (amputation free survival and major adverse limb events) probability.
Cureus
November 2024
Department of Therapeutic Processes, Faculty of Health Sciences, Universidad Católica de Temuco, Temuco, CHL.
Background: Contradictory data are available on the possible association between sarcopenia and other clinical disorders in patients with chronic kidney disease (CKD) undergoing hemodialysis.
Objective: To determine the association between sarcopenia and markers associated with systemic inflammation, fasting glycemia, and quality of life in older people with CKD undergoing hemodialysis.
Methods: This was an analytical cross-sectional study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!